On Tuesday, May 27, an analyst from BTIG downgraded Globus Medical Inc. (NYSE:GMED) from Buy to Neutral, citing concerns ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $77.5, a high ...

BTIG analysts have downgraded (NYSE:GMED) from "Buy" to "Neutral" amid fears surrounding the company's Spine business.

Globus Medical (NYSE:GMED) announced that its board of directors authorized a share repurchase program totaling up to $500 ...

Globus Medical, Inc.’s GMED share price has dipped by 21.03%, which has investors questioning if this is right time to buy.

Medical device company Globus Medical (NYSE:GMED) will be announcing earnings results tomorrow after the bell. Here’s what to expect. Globus Medical beat analysts’ revenue expectations by 3.7% ...

Globus Medical Inc is a leading innovator in the medical device industry, focusing on developing solutions for musculoskeletal disorders. With a broad portfolio, the company offers spine products ...

Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into ...

Globus Medical, Inc. GMED continues to benefit from the robust demand for its Musculoskeletal Solutions products. Following the NuVasive merger, the combined company has formed a global ...